Circulating tumor DNA holds hope for personalizing breast cancer care

Ben Ho Park, MD, PhD, said the deep knowledge and experience of the pair will optimize and personalize the prevention, diagnosis and treatment of GI malignancies.

This minimally invasive and cost-effective alternative to tissue biopsy offers “an accessible tool for tailoring treatment strategies in breast cancer,” researchers reported April 22 in the journal Science Translational Medicine.

These findings highlight the critical need for tumor genomic testing for all patients to identify those with high-risk tumors, which occur more frequently in Black women, and which require more aggressive treatment to prevent recurrence.

Lung cancer is the leading cause of cancer death in the United States, with incidence higher in veterans compared to the civilian population.

The grant extension will expand applications in research, clinical trials, registries and national collaborations.

Scientists from Vanderbilt University Medical Center and Vanderbilt University joined other advocates from Tennessee to share why continued bipartisan support for NIH is important to them.